Proteinase-Activated Receptor-2 Mediates Itch: A Novel Pathway for Pruritus in Human Skin

Martin Steinhoff,¹⁄² Ulrich Neisius,¹⁄²⁎ Akihiko Ikoma,¹ Manigé Fartasch,² Gisela Heyer,¹ Per S. Skov,² Thomas A. Luger,¹ and Martin Schmelz¹⁄⁵

Departments of ¹Physiology and Experimental Pathophysiology, and ²Dermatology, University of Erlangen, 91054 Erlangen, Germany, ³The Reference Laboratory, University of Copenhagen, 2100 Copenhagen, Denmark, ⁴Department of Dermatology, University of Münster, 48149 Münster, Germany, and ⁵Department of Anesthesiology and Intensive Care Medicine, University of Heidelberg, 68135 Mannheim, Germany

We examined whether neuronal proteinase-activated receptor-2 (PAR-2) may be involved in pruritus of human skin. The endogenous PAR-2 agonist tryptase was increased up to fourfold in atopic dermatitis (AD) patients. PAR-2 was markedly enhanced on primary afferent nerve fibers in skin biopsies of AD patients. Intracutaneous injection of endogenous PAR-2 agonists provoked enhanced and prolonged itch when applied intraleisionally. Moreover, itch upon mast cell degranulation was abolished by local antihistamines in controls but prevailed in AD patients. Thus, we identified enhanced PAR-2 signaling as a new link between inflammatory and sensory phenomena in AD patients. PAR-2 therefore represents a promising therapeutic target for the treatment of cutaneous neurogenic inflammation and pruritus.

Key words: protease-activated receptors; neuroimmunology; neurophysiology; sensory nerve; atopy; tryptase

Introduction
Recent findings on a specific pathway for itch (Schmelz et al., 1997; Andrew and Craig, 2001) have clarified the neurophysiological basis for pruritus. Histamine has been used for decades for experimental itch studies and is responsible for the induction of pruritus in some itchy dermatoses combined with mast cell degranulation like urticaria. However, it has become clear that it is not the main pruritic mediator in the majority of diseases characterized by chronic itch such as atopic dermatitis (AD) (Klein and Clark, 1999). Interestingly, proteinases like papain were identified as histamine-independent itch mediators several decades ago (Rajka, 1969; Hägermark, 1973) but have not received much attention in recent years. The identification of specific proteinase-activated receptors [proteinase-activated receptor-2 (PAR-2)] on afferent nerve fibers (Steinhoff et al., 2000) has initiated various successful studies investigating the role of PAR-2 in the pain pathway (Vergnolle et al., 2001a,b; Fiorucci and Distattu, 2002). Meanwhile, there is convincing evidence for an involvement of PAR-2 in the activation and sensitization of both somatic (Steinhoff et al., 2000; Kawabata et al., 2001) and visceral afferent nerve fibers (Corvera et al., 1999; Hoogerwerf et al., 2001; Coelho et al., 2002). Apart from its involvement in the pain pathway, recent results from PAR-2 knock-out mice also indicate a role of PAR-2 in itchy skin diseases, including atopic dermatitis (Kawagoe et al., 2002).

We therefore investigated the role of PAR-2 signaling in the induction of pruritus in AD patients. The study included measurement of intradermal concentrations of the endogenous specific PAR-2 agonist mast cell tryptase by dermal microdialysis and assessment of PAR-2 density in skin biopsies by immunohistochemistry. In addition, vascular and neuronal responses to injection of the endogenous ligand (SLIGKV) were assessed in the patients and controls.

Materials and Methods

Subjects. Thirty-three healthy volunteers (17 male, 16 female; mean ± SD age, 26.5 ± 0.9 years) and 38 AD patients (17 male, 21 female; mean ± SD age, 25.4 ± 0.5 years) participated in the study after giving informed consent. The study was approved by the local ethics committees at the University of Erlangen (microdialysis and psychophysics) and University of Münster (histology). AD was diagnosed according to the criteria of Hanifin and Rajka (1980) and Diepgen et al. (1989), using an atopy score consisting of basic and minor features of AD. The score level of AD ranged from 9 to 20 (average score level, 12). Exclusion criteria for AD patients were the following: systemic steroid therapy during the last 3 months, topical corticosteroid therapy on the volar forearm, or systemic antihistamines <3 weeks before the experiments. Healthy volunteers served as a control group; they had no signs of atopy or dermatological diseases and had not received systemic or topical corticosteroids during the last 3 months.

Microdialysis. Subjects were seated comfortably on a reclining chair in a temperature-controlled laboratory (21°C; 60% relative humidity). Up to five microdialysis catheters (0.4 mm in diameter; cutoff, 3000 kDa; DermalDialysis, Erlangen, Germany) were inserted intracutaneously at a length of 1.5 cm in the nonlesional skin of the volar forearm using a 25-gauge cannula as described previously (Weidner et al., 2000). No local anesthesia was required. All of the microdialysis catheters were oriented...
Bouin’s fixative for 12 hr, embedded in optimal cutting temperature within 2 weeks before biopsies were obtained. Tissues were fixed in agents at the sites of inflammation, systemic medications, or UV irradiating peptides (10–100 μg/ml). Polyclonal antibodies were preincubated for 24–48 hr with corresponding peptides (10–100 μM; B5, CAP Tryptase; Pharmacia & Upjohn, Freiburg, Germany) [using the protocol of Schwartz et al. (1990) for isolation of tryptase], according to the manufacturer’s instructions.

**Tethered ligand injection.** In a separate psychophysical experiment, 50 μl of Ringer’s solution containing the PAR-2 agonist SLIGKV-NH2 or the reversed peptide VKGILS-NH2 (5 × 10−4 to 5 × 10−3 μM; Bachem, Heidelberg, Germany) was injected into the volar forearm of subjects and patients in random order. They were asked to separately rate the intensity of pain and itch at intervals of 10 sec after the injection on a numerical scale from 0 (no sensation) to 10 (maximum sensation imaginable). In the patients, injections were given in visually unaffected areas of the volar forearm as well as inside their eczema in their cubital fossae. In the subjects, all of the injections were given in their cubital fossae. Injections were spaced by at least 3 cm.

**Histology.** Double immunofluorescence staining was performed with modifications as described previously (Steinhoff et al., 2000). Briefly, skin biopsies were taken from postoperative material (healthy controls; n = 6) or lesional and nonlesional skin of patients suffering from atopic dermatitis (n = 8). Patients did not receive topical antiinflammatory agents at the sites of inflammation, systemic medications, or UV irradiation within 2 weeks before biopsies were obtained. Tissues were fixed in Bouin’s fixative for 12 hr, embedded in optimal cutting temperature compound (Miles, Elkhart, IN), and stored at −80°C. Before use, specimens were sectioned, postfixed with Bouin’s fixative for 20 min, and washed in PBS, pH 7.4, for 45 min. Sections were incubated with antibodies provided by Morley Hollenberg (Johns Hopkins University, Baltimore, MD); PAR-2 B5; 1:500; kind gifts provided by Morley Hollenberg (Johns Hopkins University, Baltimore, MD); PAR-2 C-17; 1:100, Santa Cruz Biotechnology, Santa Cruz, CA) overnight at 4°C as described previously (Steinhoff et al., 2000), followed by incubation with mouse monoclonal antibody against mast cell tryptase (1:2000) for 1 hr at room temperature. After thorough washing in PBS three times for 10 min each, slides were incubated in a PBS buffer containing 5% normal goat serum and 1% bovine serum albumin with a mixture of secondary antibodies [goat anti-rabbit Ig (1:200; B5; Dako, Hamburg, Germany) or sheep anti-goat Ig (1:200; C-17; Santa Cruz Biotechnology), respectively, and donkey anti-mouse IgG (1:100; Amersham Biosciences, Braunschweig, Germany)]. After washing in a dark chamber, slides were mounted in Vectashield (Vector Laboratories, Burlingame, CA) and examined using a Leica (Nussloch, Germany) DMR microscope. In controls, primary polyclonal antibodies were preincubated for 24–48 hr with corresponding peptides (10–100 μM; B5, GPNSKGRSLIGRLDTP-YGGCG; C-17, sc8205 P; Santa Cruz Biotechnology) used for immunization, or matched monoclonal Ig control antibodies were used to elucidate background staining. Semiquantitative analysis was performed on coded sections by two independent observers as described previously (Steinhoff et al., 2000). The number of positive nerves was analyzed by counting identical staining of three subsequent slides from one block. Four blocks from four persons were counted per group. Similar regions (forearm) with comparable total numbers of nerve fibers, as determined by staining with protein gene product (PGP) 9.5 (mouse monoclonal antibody; 1:100 dilution; Accurate Chemicals, Westbury, NY), were used. Mouse tachykinin antibody was from Chemicon (Temecula, CA) (1:2000 dilution).

**Statistics.** For statistical evaluation, an ANOVA for repeated measures was used, followed by Scheffé’s post hoc tests to locate significant differences. Values of p < 0.05 were considered significant. Values are given as mean ± SEM or median and quartiles, as appropriate.

### Results

**Codeine-induced mediator release**

In AD patients, codeine-induced tryptase release exceeded by far the control values, as can be judged in the dose–response relationship (Fig. 1). Stimulated tryptase release in AD patients was more pronounced at codeine concentrations of ≥0.3 mg and reached approximately fourfold higher values after maximum stimulation with codeine.

Similarly, histamine concentration in AD was higher compared with control after insertion of the dialysis catheter (mean ± SEM, 22.4 ± 4.4 vs 9.2 ± 0.9 pg/ml; p = 53 vs 46; p < 0.01, t-test) (data not shown). However, codeine-induced histamine release did not differ significantly between the groups (Fig. 1). Mean peak levels were 287 ± 55 pg/ml (mean ± SEM; n = 12) in controls and 292 ± 39 pg/ml (mean ± SEM; n = 12) in AD.

The codeine-induced mast cell degranulation was accompanied by a dose-dependent pruritus, which did not differ significantly between the groups under control conditions. Coadministration of cetirizine in a separate session abolished codeine-induced pruritus in controls only. In contrast, AD patients still experienced moderate to medium pruritus at codeine concentrations of ≥0.3 mg/ml (Fig. 1).
Immunohistochemistry

In lesional skin of patients with atopic dermatitis, staining for PAR-2 (PAR-2 B5; red) can be observed in keratinocytes, blood vessels, certain inflammatory cells, and nerve-fiber-like structures (Fig. 2a). Nerve fibers can hardly be seen at lower magnifications because of the staining of several dermal cells. Mast cells (green) are found in dermal compartments close to blood vessels (Fig. 2a) (100×). Omission of antibodies against PAR-2 demonstrates only staining of mast cells by tryptase (Fig. 2b) (100×). Higher magnification reveals staining of small nerve fibers (arrow) in the dermis associated with blood vessels (red) and mast cells (green) (Fig. 2c) (400×). In lesional skin of patients with AD, increased staining for PAR-2 was observed in nerve fibers (arrows) closely associated with mast cells (green) (Fig. 2d) (630×) at higher magnification. Moderate staining for PAR-2 (arrows) was also observed in nerve fibers of nonlesional skin from patients with AD, whereas weak to negative staining was observed in normal human skin (Fig. 2e). Preabsorption control staining (PAR-2 B5 peptide) did not result in any PAR-2-like immunoreactivity in either human skin tissue (Fig. 2f). Identical results were obtained for both of the antisera described in Materials and Methods using the appropriate competing peptide.

Semi-quantitative analysis of immunostaining was also performed to elucidate potential differences in normal and disease skin. Therefore, we stained various tissues for PAR-2 and PGP 9.5 or Substance P (SP), respectively. Staining positivity was counted in triplicate from at least six tissues per group by using semi-quantitative analysis. Data revealed differences in PAR-2-like immunoreactivity in cutaneous nerve fibers. Of all nerves detected by staining for PGP 9.5, 63 ± 8% (n = 8; triplicate) exhibited PAR-2-like immunoreactivity in lesional skin. In nonlesional skin, 38 ± 8% (n = 6; triplicate) of all nerves stained for PGP 9.5 contained PAR-2-like immunoreactivity. We detected PAR-2-like immunoreactivity in 13 ± 10% (n = 6; triplicate) of all nerve fibers stained for PGP 9.5 in healthy volunteers. Thus, dermal nerves of atopic dermatitis show enhanced PAR-2-like immunoreactivity compared with those of normal skin. This difference was significantly increased in dermal sensory nerves stained for SP. Whereas 75 ± 8% (n = 4; triplicate) of all SP-positive nerves stained for PAR-2 in lesional skin, 46 ± 4% (n = 6; triplicate) of all nerves staining for SP also contained PAR-2-like immunoreactivity in nonlesional skin. In healthy skin, 25 ± 12% (n = 4; triplicate) of all neurons stained for SP also contained PAR-2. Together, PAR-2-like immunoreactivity was predominantly detected in sensory and, to a lesser extent, in nonsensory nerves of lesional, nonlesional, and healthy human skin. PAR-2-positive fibers are increased in lesional skin of AD patients. However, PAR-2 immunoreactivity is enhanced in nonlesional skin of AD patients compared with normal human skin. This may explain why patients with AD show increased susceptibility to itch sensations on clinically healthy skin.

PAR-2-induced sensations

Intracutaneous injection of the endogenous PAR-2 agonist SLIGKV dose-dependently provoked pain upon injection, and this pain was followed by an itch sensation lasting for ~2–5 min. Cumulative itch ratings were higher for injections in nonlesional skin of AD patients for 1 and 5 mM tethered ligand, but this difference did not reach statistical significance (p = 0.15; ANOVA; planned comparison). However, when applied inside the eczema, SLIGKV provoked enhanced itch in the patients compared with that of control (p < 0.05; ANOVA; Scheffé post hoc). At higher concentrations, the reversed peptide VKGILS also provoked an itch response (Fig. 3, right). However, at a concentration of 0.5 mM, only the active agonist SLIGKV induced an itch response, when applied in the eczema.
reverse peptide provoked itch in patients and controls, probably
sensitivity of AD patients to injection of the PAR-2-activating
and nonlesional skin nociceptors may also underlie the higher
(Bauer and Razin, 2000). Increased density of PAR-2 on lesional
nerves and mast cells may indicate functional interdependence
represents a critical finding. Moreover, the close proximity of
increased expression of PAR-2 on dermal nerves in AD patients
lesional skin; filled circles, nonlesional skin) and the reverse peptide (VKGILS-NH2; 6 controls
and 4 AD patients) are shown. Intensity of itch sensation after the injection was assessed on a
scale from 0 to 10 at 10 sec intervals for 5 min. auc, Area under the curve; mean ± SEM.

Discussion
After the identification of PAR-2 on afferent nerve fibers (Steinhoff et al., 2000), the role of proteinase-activated receptors in the pain pathway has become of major interest (Vergnolle et al., 2001a,b; Fiorucci and Distrutti, 2002). Meanwhile, there is convincing evidence for an involvement of PAR-2 for activation and sensitization of both somatic (Steinhoff et al., 2000; Kawabata et al., 2001) and visceral afferent nerve fibers (Corvera et al., 1999; Hoogerwerf et al., 2001; Coelho et al., 2002).

Interestingly, proteinases like papain were identified several decades ago to be histamine-independent itch mediators (Rajka, 1969; Hägermark, 1973). However, these observations have not received much attention in the recent past. The recent finding that, in AD patients, itch upon degranulation of mast cells could not be suppressed by antihistamines (Rukwied et al., 2000) suggested that mast cell mediators other than histamine could act as important itch mediators in AD. In line with these observations, our results indicate increased signaling via PAR-2 in AD patients, which is characterized by the release of a higher concentration of the putative endogenous PAR-2 agonist mast cell tryptase, a higher density of PAR-2 on epidermal nerves, keratinocytes, and endothelia, and finally enhanced responsiveness of the patients toward exogenously applied PAR-2 agonist.

Higher tryptase concentrations could be attributed simply to the higher number of mast cells found in AD patients (Damsgaard et al., 1997). Interestingly, only codeine-induced tryptase, but not histamine release, was found to be increased in AD. Thus, a higher level of tryptase in the mast cells or a higher percentage of tryptase-positive mast cells (Jarvikallio et al., 1997) has to be assumed. Increased tryptase levels alone cannot account entirely for the histamine-independent itch upon mast cell degranulation. The highest codeine concentration provoked considerable tryptase release in normals also, but no concomitant itch sensation was observed when H1 blockers were coapplied. Therefore, increased expression of PAR-2 on dermal nerves in AD patients represents a critical finding. Moreover, the close proximity of nerves and mast cells may indicate functional interdependence (Bauer and Razin, 2000). Increased density of PAR-2 on lesional and nonlesional skin nociceptors may also underlie the higher sensitivity of AD patients to injection of the PAR-2-activating tethered ligand. At higher concentrations, even the nonactive reverse peptide provoked itch in patients and controls, probably because of mast cell activation. It is important to note, however, that the role of human tryptase as an endogenous activator of PAR-2 is not entirely clear, because tryptase cannot activate the fully glycosylated receptor (Compton et al., 2002a,b). Thus, it is possible that either a mast cell proteinase other than tryptase may be responsible for PAR-2 activation, or the glycosylation state of PAR-2 in sensory nerves may be modulated to make the receptor susceptible to tryptase activation.

Recent results suggest that the itch sensation is processed by a specific neuronal pathway (Schmelz et al., 1997; Andrew and Craig, 2001). Enhanced itch upon application of PAR-2 agonists in the patients could therefore indicate a selective increase of PAR-2 on peripheral itch-specific neurons. However, the subtypes of unmyelinated afferent nerve fibers subserving itch or pain processing can be differentiated functionally only according to their histamine response. There is no marker available to identify itch-specific neurons, and thus, the relative increase of PAR-2 receptors cannot be compared between fibers of the pain- and itch-processing systems.

Apart from neuronal cells, increased PAR-2 signaling will also affect keratinocytes, endothelia, epithelia, smooth muscle cells, and inflammatory cells, all of which have been implicated in the pathophysiology of various chronic inflammatory diseases (Knight et al., 2001; Vergnolle et al., 2001a,b; Miotto et al., 2002), in particular atopic dermatitis. Our study confirms that PAR-2 is expressed on keratinocytes (Santulli et al., 1995) and endothelia. Activation of PAR-2 on keratinocytes (Kanke et al., 2001) and on endothelia (Shpacovitch et al., 2002) stimulates nuclear factor κB signaling, which has been speculated to be linked to atopic dermatitis (Huber et al., 2002). Moreover, PAR-2 activation increases the release of IL-6 and granulocyte–macrophage colony-stimulating factor (Wakita et al., 1997), which has been found to be elevated in keratinocytes of AD patients (Pastore et al., 2000). The importance of PAR-2 signaling for the induction of dermatitis has recently been shown by a markedly decreased contact dermatitis in PAR-2 knock-out mice (Kawagoe et al., 2002). Because PAR-2 is expressed by various inflammatory cells including mast cells (D’Andrea et al., 2000) and T cells (Bar-Shavit et al., 2002), one may speculate that PAR-2 is critically involved in both neurogenic and non-neurogenic inflammation of human skin. It should also be noted that there is a complex cross-talk among inflammatory cells with a major role in the interaction between mast cells and T cells in AD (Zhang et al., 1995; Mekori and Metcalfe, 1999; Gibbs et al., 2001; Shelburne and Ryan, 2001; Alenius et al., 2002).

In summary, proteinases appear to play an important role as itch mediators in human skin very likely by activating PAR-2. The existence of a histamine-independent, proteinase-dependent, and PAR-2-mediated itch pathway provides a new link that may lead to beneficial therapies for pruritus and cutaneous inflammation.

References
Coelho AM, Vergnolle N, Giurad B, Fioramonti J, Bueno L (2002) Protein-
ases and proteinase-activated receptor 2: a possible role to promote vis-

Compton SJ, McGuire JJ, Saifeedine M, Hollenberg MD (2002a) Restricted
ability of human mast cell tryptase to activate proteinase-activated

Compton SJ, Sandhu S, Wijesuriya SJ, Hollenberg MD (2002b) Glycosyla-
tion of human proteinase-activated receptor-2 (hPAR2): role in cell sur-

Corvera CU, Dery O, McConalogue K, Gamp P, Thoma M, Al Ani B, Caughey
GH, Hollenberg MD, Bunnett NW (1999) Thrombin and mast cell tryptase
regulate guinea-pig myenteric neurons through proteinase-

Damsgaard TE, Olesen AB, Sorensen FB, Thestrup-Pedersen K, Schiotz PO
(1989) Evaluation and relevance of atopic basic and minor features in patients with

proteinase-activated receptors-1 and -2 in human mast cell indications
for an amplified mast cell degranulation cascade. Biotech Histochem
75:85–90.

atopic basic and minor features in patients with atopic dermatitis and in
the general population. Acta Derm Venerol Suppl (Stockh) 144:50–54.


Human skin mast cells rapidly release preformed and newly generated
TNF-α and IL-8 following stimulation with anti-IgE and other secre-

Hägermark O (1973) Influence of antihistamines, sedatives, and aspirin on

Derm Venerol Suppl (Stockh) 92:44–77.

Hoogerwerf WA, Zou L, Shenoy M, Sun D, Micci MA, Lee-Hellmich H, Xiao
SY, Winston JH, Pasricha PJ (2001) The proteinase-activated receptor 2 is

IKK-2/IκBα/NF-κB pathway plays a key role in the regulation of CCR3
and eotaxin-1 in fibroblasts. A critical link to dermatitis in IκBα-deficient

Jarvikallio A, Naukkarinen A, Harvima IT, Aalto ML, Horsmanheimo M
(1997) Quantitative analysis of tryptase- and chymase-containing mast cells

Kanke T, Macfarlane SR, Seatter MJ, Davenport E, Paul A, McKenzie RC,
Plevin R (2001) Proteinase-activated receptor-2-mediated activation of
stress-activated protein kinases and inhibitory kB kinases in NCTC 2544

Peripheral PAR-2 triggers thermal hyperalgesia and nociceptive responses

Kawagoe J, Takizawa T, Matsumoto J, Tamiya M, Meek SE, Smith AJ, Hunter
proteinase-activated receptor-2 deficiency on allergic dermatitis in the

Klein PA, Clark RA (1999) An evidence-based review of the efficacy of an-
thistamines in relieving pruritus in atopic dermatitis. Arch Dermatol
135:1522–1525.

Knight DA, Lim S, Scaffidi AK, Roche N, Chung KP, Stewart GA, Thompson
of PAR-2 in respiratory epithelium from patients with asthma. J Allergy


Miotto D, Hollenberg MD, Bunnett NW, Pap A, Braccioni F, Boschetto P,

Pastore S, Giustizieri ML, Masca F, Giannetti A, Kaushansky K, Girolomoni
G (2000) Dysregulated activation of activator protein 1 in keratinocytes
of atopic dermatitis patients with enhanced expression of granulocyte/

Petersen LJ, Poulsen LK, Søndergaard J, Skov PS (1994) The use of cutane-
ous microdialysis to measure substance P-induced histamine release in

Rajka G (1969) Latency and duration of pruritus elicited by trypsin in aged

mediators other than histamine induce pruritus in atopic dermatitis pa-

Santulli RJ, Derian CK, Darrow AL, Tomko KA, Eckardt AJ, Selberg M,
Scarborough RM, Andrade-Gordon P (1995) Evidence for the presence of
a protease-activated receptor distinct from the thrombin receptor in human


and physicochemical evidence for configurational changes occurring on
conversion of human mast cell tryptase from active tetramer to inactive
monomer. Production of monoclonal antibodies recognizing active

Shellburne CP, Ryan JJ (2001) The role of Th2 cytokines in mast cell ho-

Shpacovitch VM, Brzoska T, Buddenkovte J, Stroh C, Sommerhoff CP, Ansel
Agonists of proteinase-activated receptor 2 induce cytokine release and
activation of nuclear transcription factor κB in human dermal microvas-

Steinhoff M, Vergnolle N, Young SH, Tognetto M, Amadesi S, Ennes HS,
Trevisani M, Hollenberg MD, Wallace JL, Caughey GH, Mitchell SE,
proteinase-activated receptor 2 induce inflammation by a neurogenic

Vergnolle N, Wallace JL, Bunnett NW, Hollenberg MD (2001a) Proteinase-
activated receptors in inflammation, neuronal signaling and pain. Trends

Vergnolle N, Bunnett NW, Sharkey KA, Brussee V, Compton SJ, Grady EF,
Cirino G, Gerard N, Basbaum AI, Andrade-Gordon P, Hollenberg MD,
Wallace JL (2001b) Proteinase-activated receptor-2 and hyperalgesia: a

Wakita H, Furukawa F, Takigawa M (1997) Thrombin and trypsin induce
granulocyte-macrophage colony-stimulating factor and interleukin-6
gene expression in cultured normal human keratinocytes. Proc Assoc Am

Weidner C, Kled E, Rukwied R, Lischetzki G, Neusius U, Skov PS, Petersen
LJ, Schmelz M (2000) Acute effects of substance P and calcitonin gene-

Zhang Y, Ramos BF, Jakschik B, Baganoff MP, Deppeler CL, Meyer DM,
Widomski DL, Fretland DJ, Bolanowski MA (1995) Interleukin 8 and

Zhang Y, Ramos BF, Jakschik B, Baganoff MP, Deppeler CL, Meyer DM,
Widomski DL, Fretland DJ, Bolanowski MA (1995) Interleukin 8 and